| 000 | 01612 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250514065535.0 | ||
| 264 | 0 | _c20031217 | |
| 008 | 200312s 0 0 eng d | ||
| 022 | _a1619-7070 | ||
| 024 | 7 |
_a10.1007/s00259-003-1187-0 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFrancis, D L | |
| 245 | 0 | 0 |
_aPotential impact of [18F]3'-deoxy-3'-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. _h[electronic resource] |
| 260 |
_bEuropean journal of nuclear medicine and molecular imaging _cJul 2003 |
||
| 300 |
_a988-94 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aColorectal Neoplasms _xdiagnostic imaging |
| 650 | 0 | 4 | _aDideoxynucleosides |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFluorodeoxyglucose F18 |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRadiopharmaceuticals |
| 650 | 0 | 4 | _aReproducibility of Results |
| 650 | 0 | 4 | _aSensitivity and Specificity |
| 650 | 0 | 4 |
_aTomography, Emission-Computed _xmethods |
| 650 | 0 | 4 | _aWhole-Body Counting |
| 700 | 1 | _aVisvikis, D | |
| 700 | 1 | _aCosta, D C | |
| 700 | 1 | _aArulampalam, T H A | |
| 700 | 1 | _aTownsend, C | |
| 700 | 1 | _aLuthra, S K | |
| 700 | 1 | _aTaylor, I | |
| 700 | 1 | _aEll, P J | |
| 773 | 0 |
_tEuropean journal of nuclear medicine and molecular imaging _gvol. 30 _gno. 7 _gp. 988-94 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00259-003-1187-0 _zAvailable from publisher's website |
| 999 |
_c12527864 _d12527864 |
||